Quoin Pharmaceuticals (QNRX)
(Delayed Data from NSDQ)
$0.72 USD
-0.01 (-1.63%)
Updated Jun 7, 2024 03:43 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
QNRX 0.72 -0.01(-1.63%)
Will QNRX be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for QNRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for QNRX
Endo (ENDP) Inks Deal to Develop Rare Disease Drug in Canada
QNRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for QNRX
Quoin Pharmaceuticals on the Brink: Nasdaq Deficiency Notice Threatens Stability and Investor Confidence
Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), ALX Oncology Holdings (ALXO) and Quoin Pharmaceuticals (QNRX)
QNRX Stock Earnings: Quoin Pharmaceuticals Misses EPS for Q1 2024
Quoin Pharmaceuticals Non-GAAP EPS of -$1.11 misses by $0.70
Quoin Pharmaceuticals reports Q1 EPS ($1.11) vs. ($4.09) last year